EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Therapeutic Advances in Targeting the Amyloid-β Pathway for Alzheimer’s Disease

Beiyu Zhang, Yunan Li iD, Huan Li iD, Xinai Shen iD, Zheying Zhu iD

Brain Sciences · 13.10.2025 · 15 (10) · 1101

DOI: 10.3390/brainsci15101101 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Brain Sciences, online erschienen am 13.10.2025. Verfasst von Beiyu Zhang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Molecular Therapeutics and Formulations, School of Pharmacy, The University of Nottingham, University Park Campus, Nottingham NG7 2RD, UK. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 167 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Alzheimer’s disease (AD) is the most common cause of dementia, characterized by progressive cognitive decline and neuropathological hallmarks, including amyloid-β (Aβ) plaques, neurofibrillary tangles (NFTs), and neurodegeneration. Since the amyloid cascade hypothesis was proposed, Aβ has remained a central therapeutic target, with interventions aiming to reduce Aβ production, aggregation, or downstream toxicity. This review first outlines the historical development of the Aβ hypothesis and the two major APP processing pathways (α-cleavage and β-cleavage), highlighting the role of biomarkers in early diagnosis, patient stratification, and regulatory approval. We then summarize the development and clinical outcomes of anti-Aβ small-molecule drugs, including β-secretase inhibitors, γ-secretase modulators, Aβ aggregation inhibitors, receptor/synapse modulators, and metabolic or antioxidant modalities. We further review the progression of biologic therapies, with a particular focus on monoclonal antibodies, vaccines, and emerging gene-silencing strategies, such as small interfering RNA (siRNA) and antisense oligonucleotides. Finally, we discuss future perspectives, including next-generation biologics, multi-target approaches, optimized delivery platforms, and early-prevention strategies. Collectively, these efforts underscore both the challenges and opportunities in translating anti-Aβ therapies into meaningful clinical benefits for patients with AD.

Schlagwörter

Stichwörter der Autor:innen

Alzheimer’s diseaseamyloid precursor protein (APP) processingamyloid-β hypothesisanti–amyloid-β (Aβ) vaccinesbiomarkersgene therapymonoclonal antibodiessmall-molecule drugsβ-secretase 1 (BACE1) inhibitorsγ-secretase modulators

Autor:innen und Institutionen

  • Division of Molecular Therapeutics and Formulations, School of Pharmacy, The University of Nottingham, University Park Campus, Nottingham NG7 2RD, UK.

ORCID-Profile: Yunan Li, Huan Li, Xinai Shen, Zheying Zhu

Zitieren

APA

Zhang, B., Li, Y., Li, H., Shen, X., & Zhu, Z. (2025). Therapeutic Advances in Targeting the Amyloid-β Pathway for Alzheimer’s Disease. Brain Sciences, 15(10), 1101. https://doi.org/10.3390/brainsci15101101

Vancouver

Zhang B, Li Y, Li H, Shen X, Zhu Z. Therapeutic Advances in Targeting the Amyloid-β Pathway for Alzheimer’s Disease. Brain Sciences. 2025;15(10):1101. doi:10.3390/brainsci15101101

BibTeX
@article{Zhang2025,
  author = {Zhang, Beiyu and Li, Yunan and Li, Huan and Shen, Xinai and Zhu, Zheying},
  title = {Therapeutic Advances in Targeting the Amyloid-β Pathway for Alzheimer’s Disease},
  journal = {Brain Sciences},
  year = {2025},
  volume = {15},
  number = {10},
  pages = {1101},
  doi = {10.3390/brainsci15101101}
}
Kostenlos starten →